The maker of memory chips is on course for a $1 trillion valuation, which seemed extremely unlikely one year ago.

Ripple has promised to revolutionize cross-border payments for over a decade. Wise is quietly doing it with old-fashioned ...

Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon ...

Known for its Carter’s and OshKosh brands, this childrenswear leader serves families through retail, wholesale, and digital ...

Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach ...

Both ETFs are solid options for investors looking to diversify with international stocks, but for different reasons.

Exceeding analysts' top- and bottom-line first-quarter 2026 estimates, Nebius posted strong financial results, which ...

This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor ...

Both companies are critical to the AI build-out. But one's growth profile and order book make it the more compelling buy.

Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.

Oklo aims to achieve criticality by the DOE’s Reactor Pilot Program deadline. A successful test could prove its business ...

Thursday, May 14, 2026 at 8:30 a.m. ET. CALL PARTICIPANTS. Chief Executive Officer — Michael Stein; Chief Financial Officer — ...